Orphazyme A/S (ORPH) is a global late clinical-stage biotherapeutics business engaged in the development of arimoclomol for patients with Niemann-Pick disease type C. The price
On February 23, Orphazyme A/S (ORPH) provided an update on the review of the Marketing Authorization Application (MAA) for arimoclomol in the European Union. With
On February 11, Orphazyme A/S (ORPH) provided updates regarding its NDA resubmission for arimoclomol for Niemann-Pick Disease Type-C NPC). Consequently, the stock surged in the
Orphazyme A/S (ORPH) stock prices skyrocketed by a monumental 71.24% shortly after market trading commenced on June 16th, 2021, bringing the price per share up
At Stocktstelegraph.com, we are committed to helping investors make smart and profitable decisions. Our goal is to make investing easier and more accessible to everyone. We strive to provide the best and most reliable market information, news and analysis to ensure that our readers can make informed decisions.